(NASDAQ: MRNA) Moderna's forecast annual revenue growth rate of 11.25% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 115.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.34%.
Moderna's revenue in 2026 is $2,232,000,000.On average, 27 Wall Street analysts forecast MRNA's revenue for 2026 to be $773,936,113,272, with the lowest MRNA revenue forecast at $530,542,777,296, and the highest MRNA revenue forecast at $960,290,240,496. On average, 22 Wall Street analysts forecast MRNA's revenue for 2027 to be $886,061,133,216, with the lowest MRNA revenue forecast at $430,919,501,736, and the highest MRNA revenue forecast at $1,266,973,657,416.
In 2028, MRNA is forecast to generate $1,284,554,235,456 in revenue, with the lowest revenue forecast at $388,226,044,665 and the highest revenue forecast at $3,024,640,781,904.